IP Library Granted Patent US 10,278,911
Granted Patent B2
US 10,278,911 · App. 14/708,740 · Granted May 7, 2019

Compositions containing cyclic peptides and methods of use

Inventors: Soheila Anzali (Gross-Zimmern, DE); Alfred Jonczyk (Darmstadt, DE)
Assignee: MERCK PATENT GMBH
A61K8/64A23L33/18A61K9/0014A61K38/12A61Q5/00A61Q19/00A61Q19/08C07K7/64A61K9/006A61K9/0019A61K9/0031A61K9/0043A61K9/0048A61K9/02A61K9/06A61K9/08A61K9/1075A61K9/127A61K9/19A61K9/2018A61K9/2054A61K9/286A61K9/2826A61K9/4866A61Q5/006A61Q5/02A61Q5/06A61Q5/12A61Q7/00A61Q19/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,278,911
App. No.
14/708,740
Granted
May 7, 2019
Kind
B2
Abstract

The invention relates generally to cyclic peptides and their use in compositions, especially topical, cosmetic and/or personal care compositions, and compositions containing said cyclic peptides.

Claims (52)

1. A method for reducing the visible signs of ageing of the skin in humans, wherein said visible signs of ageing of the skin are selected from the group consisting of stretch marks of the skin, wrinkles, skin lines, roughness of the skin, loss of skin elasticity, loss of skin firmness, loss of skin tightness, and slack tissue, comprising administering to a portion of the skin of said human showing said visible signs of ageing a composition for topical use and/or a cosmetic composition, said composition being a liposome composition comprising

i) 0.001 to 1% by weight of cyclo-(Arg-Gly-Asp-DPhe-Acha) and/or a salt thereof, wherein at least 10% of the Cyclo-(Arg-Gly-Asp-DPhe-Acha) and/or the salt thereof is entrapped in liposomes,

ii) 0.01 to 20% by weight of one or more lipids,

iii) 60 to 99.99% by weight of one or more physiologically acceptable solvents, and optionally

iv) 0.0001 to 20% by weight of one or more further ingredients, selected from the group consisting of

α) further active compounds having a skin-care, hair-care and/or inflammation-inhibiting action, and

β) further cosmetically acceptable excipients.

2. The method according to claim 1 , wherein in the liposome composition, the lipids comprise one or more of the following:

a) phospholipids,

b) glycosphingolipids,

c) lecithin,

d) spingomyelin,

e) dipalmitoyl lecithin,

f) distearoylphosphatidylcholine,

g) phosphatidylcholine,

h) saturated phosphatidylcholine,

i) unsaturated phosphatidylcholine,

j) polystyrene,

k) octyldodecanol, optionally in combination with Silica,

l) octyldodecanol, optionally in combination with phospholipids, cholesterol and/or glycospingolipids,

and/or one or more salts thereof.

3. The method according to claim 1 , wherein in the liposome composition, the one or more physiologically acceptable solvents comprise:

water, and/or

an alcohol having 2 to 5 carbon atoms, which is ethanol, isopropanol, glycerin, 1,2-propylene glycol, 1,4-butanediol, pentylene glycol, sorbitol or a mixture thereof.

4. The method according to claim 1 , wherein the liposome composition comprises

i) 0.001 to 1% by weight of cyclo-(Arg-Gly-Asp-DPhe-Acha), and/or a salt thereof,

ii) 0.01 to 20% by weight of one or more lipids,

iii) 70 to 99% by weight of one or more physiologically acceptable solvents, and optionally

iv) 0.001 to 10% by weight of one or more further ingredients, selected from the group consisting of

α) further active compounds having a skin-care, hair-care and/or inflammation-inhibiting action, and

β) further cosmetically acceptable excipients.

5. The method according to claim 1 , wherein in the liposome composition, the further active compounds having a skin-care, hair-care and/or inflammation-inhibiting action comprises ectoin in an amount of 0.1 to 1% by weight.

6. The method according to claim 1 , wherein in the liposome composition, the further active compounds having a skin-care, hair-care and/or inflammation-inhibiting action comprises ectoin in an amount of 1% by weight.

7. The method according to claim 1 , wherein in the liposome composition, the further active compounds having a skin-care, hair-care and/or inflammation-inhibiting action comprises ectoin in an amount of up to 3% by weight.

8. The method according to claim 1 , wherein in the liposome composition, at least 20% of the Cyclo-(Arg-Gly-Asp-DPhe-Acha) and/or the salts thereof is entrapped in liposomes.

9. The method according to claim 1 , wherein in the liposome composition, at least 50% of the Cyclo-(Arg-Gly-Asp-DPhe-Acha) and/or the salts thereof is entrapped in liposomes.

10. The method according to claim 1 , wherein in the liposome composition, at least 75% of the Cyclo-(Arg-Gly-Asp-DPhe-Acha) and/or the salts thereof is entrapped in liposomes.

11. The method according to claim 1 , wherein in the liposome composition, at least 95% of the Cyclo-(Arg-Gly-Asp-DPhe-Acha) and/or the salts thereof is entrapped in liposomes.

12. The method according to claim 1 , wherein in the liposome composition, the one or more lipids are selected from the group consisting of lecithin, spingomyelin, dipalmitoyl lecithin, distearoylphosphatidylcholine, phosphatidylcholine, saturated phosphatidylcholine and unsaturated phosphatidylcholine, or is a mixture thereof or is a salt thereof.

13. The method according to claim 1 , wherein the liposome composition comprises 0.05 to 0.5% by weight of cyclo-(Arg-Gly-Asp-DPhe-Acha), and/or a salt thereof.

14. The method according to claim 1 , wherein the liposome composition comprises 2 to 10% by weight of one or more lipids.

15. The method according to claim 1 , wherein the liposome composition comprises 0.0001 to 20% by weight of one or more further ingredients, which are selected from the group consisting of

α) further active compounds having a skin-care, hair-care and/or inflammation-inhibiting action, and

β) further cosmetically acceptable excipients.

16. The method according to claim 1 , wherein said visible signs of ageing of the skin is stretch marks of the skin.

17. The method according to claim 1 , wherein said visible signs of ageing of the skin is wrinkles.

18. The method according to claim 1 , wherein said visible signs of ageing of the skin is skin lines.

19. The method according to claim 1 , wherein said visible signs of ageing of the skin is roughness of the skin.

20. The method according to claim 1 , wherein said visible signs of ageing of the skin is loss of skin elasticity.

21. The method according to claim 1 , wherein said visible signs of ageing of the skin is loss of skin firmness.

22. The method according to claim 1 , wherein said visible signs of ageing of the skin is loss of skin tightness.

23. The method according to claim 1 , wherein said visible signs of ageing of the skin is slack tissue.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2015
From: JONCZYK, ALFRED; ANZALI, SOHEILA
To: MERCK PATENT GMBH
Reel/Frame 036150/0577 →
Priority Claims (1)
EP 08006968 · Apr 8, 2008 · regional
Continuity (2)
Division 12936761
Related Publication 20150265516A1 · Sep 24, 2015